Acorn Bioventures Acquires 5% Stake in OnKure Therapeutics, Inc.

On March 27, 2026, Acorn Bioventures and its affiliated entities disclosed a significant new position in OnKure Therapeutics, Inc. (OKUR). The filing, submitted via Schedule 13G, reveals that Acorn Bioventures 2, L.P. and Acorn Capital Advisors GP 2, LLC beneficially own 2,069,512 shares of common stock, representing a 5.0% ownership stake. This position includes 939,782 shares issuable upon the exercise of warrants. Additionally, Anders Hove, acting as Manager for the general partners of both Acorn Bioventures, L.P. and Acorn Bioventures 2, L.P., is deemed to have shared voting and dispositive power over an aggregate of 3,924,037 shares, or approximately 9.5% of the company. The ownership calculations account for a private placement of 26,713,636 shares and are subject to a 9.9% beneficial ownership blocker on warrant exercises. The reporting persons certified that the shares were acquired in the ordinary course of business and not for the purpose of influencing control over the issuer.